CAPR - Capricor Therapeutics reports Q3 results November, 12 2020 04:07 PM Capricor Therapeutics Inc. Capricor Therapeutics (CAPR): Q3 GAAP EPS of -$0.20.Revenue of $0.02M (-85.7% Y/Y) Cash, equivalents and marketable securities totaled ~$35.3M.Press Release For further details see: Capricor Therapeutics reports Q3 results